Welcome to our dedicated page for Staar Surg news (Ticker: STAA), a resource for investors and traders seeking the latest updates and insights on Staar Surg stock.
Staar Surgical Co (STAA) delivers innovative vision correction solutions through advanced implantable lenses for refractive and cataract surgery. This news hub provides investors and medical professionals with essential updates on the company's technological advancements and market position.
Access consolidated coverage of earnings reports, product approvals, and strategic partnerships impacting the ophthalmic devices sector. Our repository includes official press releases about ICL technology developments, international regulatory milestones, and clinical study outcomes.
Stay informed about STAA's progress in minimally invasive surgical solutions through verified updates on manufacturing expansions, R&D investments, and surgeon training initiatives. Bookmark this page for real-time tracking of developments affecting the company's role in improving global vision care standards.
Broadwood Partners, which owns 30.2% of STAAR common stock, criticized STAAR Surgical’s fourth postponement of the shareholder vote on the proposed sale to Alcon (NYSE: ALC).
The Special Meeting was rescheduled from December 19, 2025 to January 6, 2026. Broadwood called the transaction ill-advised, urged shareholders to vote AGAINST the deal, and said several large shareholders, all three proxy advisory firms, and at least one director have expressed skepticism about the process, timing, and price.
Alcon (SIX/NYSE: ALC) has exercised its right under the merger agreement to require STAAR Surgical (NASDAQ: STAA) to adjourn its Special Meeting of Stockholders.
The Special Meeting originally set for December 19, 2025 at 8:30 a.m. Pacific Time is adjourned to January 6, 2026 at 8:30 a.m. Eastern Time. The record date for eligible STAAR stockholders remains the close of business on October 24, 2025. Stockholders with voting questions should contact STAAR's proxy solicitor, Innisfree M&A Incorporated, using the provided phone numbers for stockholders and intermediaries.
Broadwood Partners (major shareholder) sent an open letter to the STAAR Surgical board urging fellow shareholders to vote AGAINST the proposed sale to Alcon (NYSE: ALC) ahead of the special meeting scheduled for December 17, 2025. Broadwood says it owns 30.2% of STAAR, believes the deal materially undervalues the company, and pledges to cooperate with the board if the transaction fails.
Key points: Broadwood projects a path to $50 per share next year if STAAR remains independent, cites inventories normalizing in China and upcoming product launches, and calls for board leadership changes to restore shareholder confidence.
Yunqi Capital, a 5.1% shareholder of STAAR (NASDAQ: STAA), urged shareholders on December 17, 2025 to reject Alcon’s amended acquisition offer of $30.75 and back STAAR’s standalone trajectory.
Yunqi said proxy adviser Glass Lewis continues to oppose the merger while ISS flipped in favor but noted shareholders could reasonably remain opposed. Yunqi criticized STAAR’s go-shop process (company engaged with 21 third parties) and highlighted upcoming catalysts including a January 2026 launch of EVO ICL V5, which the firm says could carry a 30–70% premium to existing ICL pricing.
STAAR Surgical (NASDAQ:STAA) announced that independent analysts and proxy advisor ISS view the amended Alcon (SIX/NYSE:ALC) merger as providing value to STAAR stockholders. Under the revised agreement dated December 9, 2025, STAAR stockholders would receive $30.75 per share in cash, equal to a 74% premium to STAAR's 90-day VWAP as of August 4, 2025 and a 66% premium to the August 4 closing price.
Analysts cited a ~$1.6bn all-in valuation (~4.5x forward EV/Sales using blended 2026–2027 estimates of $271m and $300m) and noted limited competing bids after the go-shop. ISS updated its report to recommend shareholders vote FOR. A virtual Special Meeting is set for December 19, 2025.
FAQ
What is the current stock price of Staar Surg (STAA)?
What is the market cap of Staar Surg (STAA)?
